Congenital Cytomegalovirus Infection
2
Pipeline Programs
6
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Biotest PharmaceuticalsBT097
Human BioSciencesCMV hyperimmune globulin
Allergy TherapeuticsLetermovir
Clinical Trials (3)
Total enrollment: 459 patients across 3 trials
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
Start: Nov 2021Est. completion: Mar 202448 patients
Phase 3Terminated
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Start: Apr 2012Est. completion: Jun 2021399 patients
Phase 3Completed
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Start: Feb 2025Est. completion: Aug 202612 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 459 patients
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.